Skip to main content
Inovio reports on Phase I data from HIV vaccine PENNVAX GP trial

Inovio Pharmaceuticals announced its early-stage trial to assess its HIV vaccine PENNVAX GP had achieved positive preliminary results, indicating that the vaccine produced durable, robust immune responses in the participants six months after they were given the last dose. The data was presented at the HIV Vaccine Trials Network meeting.

Full Story: